Primed with early stage research supporting the bone-building activity of its small-molecule alternative to existing therapies, Los Angeles-based Max Biopharma Inc. is on the hunt for a $12 million series A financing to help it move closer to filing FDA investigational device exemption (IDE) and new drug (IND) applications as it advances localized and systemic bone formation programs.